Nucleolar organiser region associated proteins in cutaneous melanotic lesions: a quantitative study

J CROCKER, N SKILBECK

From the Department of Histopathology, East Birmingham Hospital, Bordesley Green East, Birmingham

SUMMARY  Using a silver staining technique, nucleolar organiser regions were identified in routinely processed paraffin sections of a range of dermal melanotic lesions. The technique shows argyrophilic NOR associated proteins (AgNORs), which are seen in nuclei as black dots. Although the nuclei of melanocarcinoma in situ, melanocarcinoma per se, and lentigo maligna contained similar numbers of AgNORs, in melanocarcinomas a mean of 7.9 AgNORs per nucleus was found, while in naevocellular naevi, this figure was 1.2. The AgNOR method, which is unknown to most histopathologists, could perhaps be used quantitatively or semiquantitatively to assist in the diagnosis of melanotic lesions in the skin (and elsewhere).

Nucleolar organiser regions (NORs) are loops of ribosomal DNA (rDNA) which occur in nucleoli and ultimately direct ribosome and protein formation. The NOR DNA possesses ribosomal RNA (rRNA) genes which are transcribed by RNA polymerase I. NOR-associated proteins and NORs themselves have been visualised in the past by cytogeneticists using a simple argentophilic (AgNOR) technique. This has been used for the detection of certain trisomies—notably, that of chromosome 21. More recently, it has been suggested that the numbers of AgNORs in nuclei may reflect their state of activation or, indeed, malignancy.

In view of these findings NORs have recently been studied in malignant lymphomas using a silver staining (AgNOR) technique. This showed that the numbers of demonstrable NORs in paraffin sections of lymphomas reflected their degree of (histological) malignancy. Accordingly, we applied the method to another field of histopathology where the assessment of malignancy may be difficult—namely that of melanotic skin lesions.

Material and methods

Fifty melanotic skin lesions were studied. These comprised: 10 melanocarcinomas, 10 intradermal naevocellular naevi, 10 compound naevocellular naevi, five junctional naevi, five superficial spreading melanomas, three cases of lentigo maligna, two of cellular blue naevus and five juvenile melanomas. These were taken from routine files at this hospital. They had been fixed in 10% formalin and processed to paraffin wax. Sections were cut at 3 µm thickness and were taken to water via xylene and graded ethanols.

The sections were submitted to the AgNOR procedure at room temperature for 30 minutes. The reaction mixture comprised 2% gelatin in 1% aqueous formic acid. This was mixed in a proportion of 1:2 volumes with 50% aqueous silver nitrate under dark room conditions. After staining the mixture was poured from the slides. Counterstaining was not performed, and the sections were dehydrated to xylene and mounted in synthetic medium.

Sections were examined under an oil immersion lens at a magnification of 1000, and 100 nuclei were studied. The AgNOR “dots” in these were counted by a simple eyepiece graticule (to prevent recounting). Preliminary experiments showed this method to be no more time consuming than the use of a semiautomatic image analyser. The mean number of AgNORs per nucleus was calculated for each specimen. In all cases the AgNORs in randomly selected naevus or melanocarcinoma cells were counted. The AgNORs in adjacent normal epidermis, adnexae, and lymphocytes were not included.

Results

In all specimens AgNORs were clearly visible as black dots of varying sizes in the nuclei. In general, these were present over nucleoli, but often smaller
AgNORs could be seen lying away from main nuclear structures. The AgNORs were easily counted. Cytoplasmic melanin, where present, was stained black; this did not obscure nuclear AgNORs.

The highest numbers of AgNORs were seen in melanocarcinomas (7.1–11.6; mean 8.23; SEM 0.57) and in superficial spreading melanomas (5.8–10.1; mean 8.06; SEM 0.78) (figs 1 and 2). Where lympho-
cytes were observed in association with these lesions, they possessed only a mean of 1·1 AgNOR per nucleus. (fig 3) Lentigo maligna also showed numerous AgNORs (5·8–9·1; mean 7·4; SEM 0·94). In striking contrast, intradermal naevi (0·8–1·5; mean 1·16; SEM 0·07) (fig 4), compound naevi (0·8–1·4; mean 1·1; SEM 0·06), junctional naevi (1·0–1·4; mean 1·18; SEM 0·08) (fig 5), cellular blue juvenile melanomas (1·2–1·3; mean 1·25; SEM 0·05), and juvenile melanomas (1·0–1·6; mean 1·36; SEM 0·1) possessed strikingly fewer AgNORs than the malignant lesions. Where naevus cells were large or “giant” they possessed two or three AgNORs but, of course, the mean AgNOR count was not affected by these occasional cells.

The pooled mean AgNOR numbers per nucleus for the benign group of lesions was 1·21 and for the malignant group 7·9 (significance of difference p > 0·001, Student’s t test). In the normal adjacent epidermis the basal layer cells possessed three to four AgNORs per nucleus. As maturation occurred towards the surface, this number declined to one AgNOR per nucleus. The basal cells were readily distinguished from the malignant melanocytes in the epidermis (table, fig 6).

Table
Ranges and mean Nos of AgNORs per nucleus in the skin lesions studied

<table>
<thead>
<tr>
<th>Case Nos</th>
<th>Intradermal naevocellular naevus</th>
<th>Compound naevocellular naevus</th>
<th>Junctional naevocellular naevus</th>
<th>Cellular blue naevus</th>
<th>Juvenile melanoma</th>
<th>Lentigo maligna</th>
<th>Superficial spreading melanoma</th>
<th>Melanocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1·1</td>
<td>1·0</td>
<td>1·3</td>
<td>1·3</td>
<td>1·6</td>
<td>5·8</td>
<td>6·7</td>
<td>7·5</td>
</tr>
<tr>
<td>2</td>
<td>1·2</td>
<td>1·4</td>
<td>1·2</td>
<td>1·2</td>
<td>1·4</td>
<td>9·1</td>
<td>8·9</td>
<td>4·2</td>
</tr>
<tr>
<td>3</td>
<td>1·0</td>
<td>1·1</td>
<td>1·0</td>
<td>1·0</td>
<td>1·0</td>
<td>7·3</td>
<td>10·1</td>
<td>7·9</td>
</tr>
<tr>
<td>4</td>
<td>0·9</td>
<td>0·8</td>
<td>1·0</td>
<td>1·3</td>
<td>1·3</td>
<td>5·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>5</td>
<td>1·4</td>
<td>1·3</td>
<td>1·4</td>
<td>1·5</td>
<td>1·5</td>
<td>8·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>6</td>
<td>1·3</td>
<td>1·4</td>
<td>1·4</td>
<td>1·5</td>
<td>1·5</td>
<td>8·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>7</td>
<td>1·1</td>
<td>1·1</td>
<td>1·1</td>
<td>1·5</td>
<td>1·5</td>
<td>8·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>8</td>
<td>0·8</td>
<td>0·9</td>
<td>0·9</td>
<td>1·5</td>
<td>1·5</td>
<td>8·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>9</td>
<td>1·3</td>
<td>1·0</td>
<td>1·0</td>
<td>1·5</td>
<td>1·5</td>
<td>8·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>10</td>
<td>1·5</td>
<td>1·0</td>
<td>1·0</td>
<td>1·5</td>
<td>1·5</td>
<td>8·8</td>
<td>8·8</td>
<td>8·5</td>
</tr>
<tr>
<td>Mean</td>
<td>1·16</td>
<td>1·1</td>
<td>1·18</td>
<td>1·25</td>
<td>1·36</td>
<td>7·4</td>
<td>8·06</td>
<td>8·23</td>
</tr>
<tr>
<td>SD</td>
<td>0·22</td>
<td>0·21</td>
<td>0·19</td>
<td>0·07</td>
<td>0·23</td>
<td>1·65</td>
<td>1·76</td>
<td>1·87</td>
</tr>
<tr>
<td>SEM</td>
<td>0·07</td>
<td>0·06</td>
<td>0·08</td>
<td>0·05</td>
<td>0·1</td>
<td>0·94</td>
<td>0·78</td>
<td>0·57</td>
</tr>
</tbody>
</table>
and rRNA should be of essential importance in cell activity.

We followed the modified method of Ploton et al, who ran the reaction at 20°C rather than at the traditional 60°C and found less background staining and deposit. These authors showed that in a small series of prostatic specimens there were multiple AgNORs in carcinomas, compared with only two in hyperplasias. The modified one step sequence has also enabled AgNORs to be shown at the ultrastructural level.13 14

This study has shown that there is a clear quantitative difference between the AgNOR content of the cells of malignant melanotic skin lesions and that of benign lesions. The difference is of such a magnitude that formal quantification would not be necessary for the histopathologist faced with making the distinction. Indeed, it is not proposed that the reported figures are absolute as 3μm sections of much larger structures—that is, cell nuclei—have been studied. The distinction between benign and malignant lesions in this context is, of course, essential and may be difficult in routine sections. Interestingly, the cells of superficial spreading melanoma and lentigo maligna differed from the cells of, for example, junctional naevi in their AgNOR content as this is sometimes a difficult diagnostic area. The observation that the basal layer of normal epidermis possessed more AgNORs per nucleus than do the more superficial cells, agrees with similar findings reported for tonsillar epithelium.6

It may be that the numbers of AgNORs in a cell reflect its degree of ploidy. In view of the known numbers of chromosomes bearing AgNORs referred to above, however, it seems that, in view of the presence of only about one AgNOR in benign naevus cells and melanocytes, there is variable expression of NOR-associated proteins. The possibility that NOR activity should be related to cellular activity and thus, perhaps, transformation and malignancy, has previously been noted.5 6

We thank Mrs Ruth Fry for wordprocessing and Mr MJ Chard for photographic help.

References

NORs in melanotic lesions


Requests for reprints to: Dr J Crocker, Department of Histopathology, East Birmingham Hospital, Bordesley Green East, Birmingham B9 5ST, England.
Nucleolar organiser region associated proteins in cutaneous melanotic lesions: a quantitative study.
J Crocker and N Skilbeck

doi: 10.1136/jcp.40.8.885

Updated information and services can be found at: [http://jcp.bmj.com/content/40/8/885](http://jcp.bmj.com/content/40/8/885)

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)